PE20040722A1 - Formas cristalinas del acido 3-metiltiofen-2-carboxilico - Google Patents

Formas cristalinas del acido 3-metiltiofen-2-carboxilico

Info

Publication number
PE20040722A1
PE20040722A1 PE2003000741A PE2003000741A PE20040722A1 PE 20040722 A1 PE20040722 A1 PE 20040722A1 PE 2003000741 A PE2003000741 A PE 2003000741A PE 2003000741 A PE2003000741 A PE 2003000741A PE 20040722 A1 PE20040722 A1 PE 20040722A1
Authority
PE
Peru
Prior art keywords
methylthiophen
crystalline forms
carboxyl acid
refers
same
Prior art date
Application number
PE2003000741A
Other languages
English (en)
Inventor
Guido Jordine
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20040722A1 publication Critical patent/PE20040722A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A FORMAS CRISTALINAS POLIMORFICAS DE (6S,9R,10S,11S,13S,16R,17R)-9-CLORO-6-FLUORO-11-HIDROXI-17-METOXICARBONIL-10,13,16-TRIMETIL-3-OXO-6,7,8,9,10,11,12,13,14,15,16,17-DODECAHIDRO-3H-CICLOPENTA[a]FENANTREN-17-ILESTER DEL ACIDO 3-METILTIOFEN-2-CARBOXILICO QUE PUEDEN SER A O B. LA FORMA A TIENE UN PUNTO DE FUSION DE 264 °C Y LINEAS DE DIFRACCION CARACTERISTICAS (2q EN GRADOS ANGULARES ± 0.2°) EN EL PATRON DE RAYOS X DEL MISMO: 3.6°, 7.3°, 13.4°, 14.6°, 18.3°, 22.0°, 25.8°, 25.9°, 29.5°; Y LA FORMA B CUYO PUNTO DE FUSION ES 270°C Y LINEAS DE DIFRACCION CARACTERISTICAS (2q EN GRADOS ANGULARES ± 0.2°) EN EL PARON DE RAYOS X DEL MISMO: 7.2°, 9.3°,12.0°, 12.8°, 13.1°, 14.5°, 17.4°, 20.4°, 23.2° Y 25.8°. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA EN FORMA INHALABLE. DICHOS COMPUESTOS TIENEN UNA ALTA ACTIVIDAD ANTI-INFLAMATORIA
PE2003000741A 2002-07-29 2003-07-25 Formas cristalinas del acido 3-metiltiofen-2-carboxilico PE20040722A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0217504.0A GB0217504D0 (en) 2002-07-29 2002-07-29 Organic compounds

Publications (1)

Publication Number Publication Date
PE20040722A1 true PE20040722A1 (es) 2004-11-29

Family

ID=9941275

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000741A PE20040722A1 (es) 2002-07-29 2003-07-25 Formas cristalinas del acido 3-metiltiofen-2-carboxilico

Country Status (30)

Country Link
US (1) US7683048B2 (es)
EP (2) EP1676854A1 (es)
JP (1) JP2006501207A (es)
KR (1) KR100688371B1 (es)
CN (1) CN1305892C (es)
AR (1) AR040692A1 (es)
AT (1) ATE349459T1 (es)
AU (1) AU2003251651B2 (es)
BR (1) BR0313044A (es)
CA (1) CA2493330C (es)
CY (1) CY1106406T1 (es)
DE (1) DE60310747T2 (es)
DK (1) DK1554303T3 (es)
EC (1) ECSP055579A (es)
ES (1) ES2279970T3 (es)
GB (1) GB0217504D0 (es)
HK (1) HK1080484B (es)
IL (2) IL166287A0 (es)
MX (1) MXPA05001173A (es)
MY (1) MY136407A (es)
NO (1) NO20050806L (es)
NZ (2) NZ549713A (es)
PE (1) PE20040722A1 (es)
PL (1) PL209409B1 (es)
PT (1) PT1554303E (es)
RU (2) RU2348646C1 (es)
SI (1) SI1554303T1 (es)
TW (1) TWI309164B (es)
WO (1) WO2004013156A1 (es)
ZA (1) ZA200500370B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0603783D0 (en) * 2006-02-24 2006-04-05 Novartis Ag Organic compounds
EP2280708A1 (en) * 2008-03-14 2011-02-09 Otsuka Pharmaceutical Co., Ltd. Mmp-2 and/or mmp-9 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU550939A1 (ru) * 1975-05-19 1994-07-15 Институт химии древесины АН ЛатвССР 1,2,3,4,4а,4в,5,6,10,10а -декагидро -6- хлорацетоксиметил -1,4а-диметил -7- (1-метилэтил) -1- фенантренкарбоновая кислота или ее соли
JPH08291073A (ja) * 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 医薬品組成物及びその製造方法
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
GB0217504D0 (en) 2002-09-04
MXPA05001173A (es) 2005-05-16
CY1106406T1 (el) 2011-10-12
NO20050806L (no) 2005-02-15
CN1671731A (zh) 2005-09-21
MY136407A (en) 2008-09-30
SI1554303T1 (sl) 2007-06-30
RU2005105688A (ru) 2005-10-10
ZA200500370B (en) 2006-07-26
ES2279970T3 (es) 2007-09-01
DK1554303T3 (da) 2007-04-30
DE60310747T2 (de) 2007-10-11
EP1554303B1 (en) 2006-12-27
US7683048B2 (en) 2010-03-23
BR0313044A (pt) 2005-06-14
PL373140A1 (en) 2005-08-22
WO2004013156A1 (en) 2004-02-12
KR20050033632A (ko) 2005-04-12
CN1305892C (zh) 2007-03-21
ECSP055579A (es) 2005-04-18
RU2330043C2 (ru) 2008-07-27
IL166287A0 (en) 2006-01-15
AU2003251651A1 (en) 2004-02-23
EP1676854A1 (en) 2006-07-05
NZ537868A (en) 2006-11-30
HK1080484A1 (en) 2006-04-28
PT1554303E (pt) 2007-03-30
CA2493330C (en) 2011-08-23
ATE349459T1 (de) 2007-01-15
KR100688371B1 (ko) 2007-03-02
US20060166954A1 (en) 2006-07-27
TWI309164B (en) 2009-05-01
RU2007143025A (ru) 2009-01-20
NZ549713A (en) 2008-04-30
HK1080484B (zh) 2007-08-03
TW200401633A (en) 2004-02-01
IL184848A0 (en) 2007-12-03
EP1554303A1 (en) 2005-07-20
CA2493330A1 (en) 2004-02-12
AR040692A1 (es) 2005-04-13
PL209409B1 (pl) 2011-08-31
AU2003251651B2 (en) 2007-07-12
RU2348646C1 (ru) 2009-03-10
DE60310747D1 (en) 2007-02-08
JP2006501207A (ja) 2006-01-12

Similar Documents

Publication Publication Date Title
EE04965B1 (et) Imidasoimidasoolid ja triasoolid kui p?letikuvastased hendid, nende kasutamine ravimite valmistamiseks ning farmatseutiline kompositsioon
PL401469A1 (pl) Pochodna azabicykliczna, sposób jej wytwarzania, jej zastosowanie w medycynie oraz zawierajaca pochodna kompozycja
RS51764B (en) TRANSDERMAL PHARMACEUTICAL COMPOSITION
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
PE20020529A1 (es) Forma de dosificacion farmaceutica con multiples recubrimientos para reducir el impacto de fracturas del recubrimiento
HUP0400333A3 (en) Crystalline anticholinergic, method for its production, and use thereof in the production of pharmaceutical composition
EE200100010A (et) Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
IL167250A (en) Chirale oxazole-arylpropionic acid derivatives, compositions comprising thereof and their use in the preparation of medicaments for the treatment of ppar alpha/ ppar gamma agonists-modulated diseases
AU2003215245A1 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
ITTO20020524A0 (it) Formulazione a rapida assimilazione preferibilemnte sotto forma di compressa rivestita per uso medico
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
HUP0401569A2 (hu) Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra
AU2003271510A1 (en) Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
PE20040722A1 (es) Formas cristalinas del acido 3-metiltiofen-2-carboxilico
WO2006041843A3 (en) Pharmaceutical dosage form comprising meloxicam
EE200200057A (et) Kasvutegurit IL-5 pärssiv asauratsiilderivaat, selle saamine ja kasutamine ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
IL169428A (en) Acylaminothiazole derivatives, preparation method thereof, pharmaceutical compositions comprising them and use of same in the manufacture of beta-amyloid peptide production inhibitors
HK1081864A1 (en) Anti-inflammatory compositions and use of the same in the manufacture of medicaments
BR0012184B1 (pt) compostos derivados de indol, formulação farmacêutica, e, composição e uso dos compostos na fabricação de medicamentos
EE200100051A (et) Vastavast (-)-stereoisomeerist põhiliselt vaba (+)-nortsisapriidi või selle farmatseutiliselt vastuvõetava soola kasutamine ja farmatseutiline kompositsioon
AU2003257982A1 (en) Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
AR033331A1 (es) Formas polimorfas de un citrato de azabiciclo [2,2,2] octan-3-amina, sus composiciones farmaceuticas, procedimiento de tratamiento y procedimiento para su produccion.
GEP20043300B (en) Amorphous Torasemide Modification
AR015190A1 (es) Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento

Legal Events

Date Code Title Description
FC Refusal